Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.50 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 5/20 | 0.49 |
| ▸ | ITGA1 | P56199 | 4/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989670 | 1.00 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL30174305 | 1.00 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29601701 | 1.00 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29601883 | 1.00 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL25310386 | 0.93 | HDAC3 (0.55) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL162018 | 0.93 | HDAC3 (0.55) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29602402 | 0.93 | HDAC3 (0.55) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29601720 | 0.93 | HDAC3 (0.55) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL17867151 | 0.91 | GAA (0.51) | HDAC8 | |
| SCHEMBL3124456 | 0.91 | GAA (0.51) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-04-14 | — | — | US | disclosed |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-04-20 | — | — | US | disclosed |
| US-11267816-B2 | Selective Grp94 inhibitors and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-03-08 | — | — | US | disclosed |
| US-8492345-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492345-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | NORTHWESTERN UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| US-8058244-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058244-B2 | Cyclic peptide antitumor agents | NORTHWESTERN UNIVERSITY (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | SILVERMAN RICHARD B | 2010-08-12 | — | — | US | disclosed |
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | SILVERMAN RICHARD B | 2010-08-12 | — | — | US | disclosed |
| US-7709443-B2 | For treatment of human melanoma, pancreatic, breast, prostate cancer cells | NORTHWESTERN UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709443-B2 | For treatment of human melanoma, pancreatic, breast, prostate cancer cells | NORTHWESTERN UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204088-A1 | Cyclic Peptide Antitumor Agents | VIP, IAPP, NGLY1 | HDAC3 3132/4885HDAC1 1488/4885HDAC2 3800/4885 |
| US-20120122799-A1 | CYCLIC PEPTIDE ANTITUMOR AGENTS | VIP, IAPP, NGLY1 | HDAC3 3132/4885HDAC1 1488/4885HDAC2 3800/4885 |
| US-11267816-B2 | Selective Grp94 inhibitors and uses thereof | HSP90B1, HSP90AB2P, HSPE1 | HDAC3 3072/4885HDAC1 2595/4885HDAC2 3178/4885 |
| US-12600725-B2 | Selective GRP94 inhibitors and uses thereof | GRPR, HSPB1, HSP90AB2P | HDAC3 1475/4885HDAC1 1787/4885HDAC2 1419/4885 |
| US-20230123747-A1 | SELECTIVE GRP94 INHIBITORS AND USES THEREOF | HSP90B1, HSP90AB2P, HSPE1 | HDAC3 3072/4885HDAC1 2595/4885HDAC2 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.